Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Treatment of Peri-implantitis With or Without Simultaneous Soft Tissue Augmentation

19 juni 2026 uppdaterad av: Lucrezia Paternò Holtzman, George Eastman Dental Hospital, Italy

Surgical Reconstructive Treatment of Peri-Implantitis With or Without Simultaneous Soft Tissue Augmentation: a Multi-center Randomized Controlled Trial

The study will aim to compare two modalities in the reconstructive treatment of peri-implantitis defects. More specifically, the control group will be a reconstructive approach (xenograft bone graft granules and collagen membrane, BioOss and BioGide, Geistlich, Wolhusen). The test group will be the same, with the exception of an autologous sub-epithelial connective tissue palatal graft, sutured beneath the flap, which will be used in addition to grafting materials.

Outcomes will include CAL, PD, MR, defect resolution, PI, BoP, SUPP, surgical characteristics, and patient-reported outcome measures, including an aesthetic self-evaluation.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

The study will aim to compare two modalities in the reconstructive treatment of peri-implantitis defects.

More specifically, the control group will be a "pure" reconstructive approach (xenograft bone graft granules and resorbable collagen membrane, BioOss and BioGide, Geistlich, Wolhusen). This is in accordance with gold standard practices of reconstructive therapy of peri-implant defects.

The test group will be treated with the same approach and materials, with the exception of an autologous sub-epithelial connective tissue palatal graft, sutured beneath the flap, which will be used in addition to the grafting materials. The graft will be harvested from the homolateral palate (molar region).

Outcomes will include clinical attachment level (CAL; primary outcome), probing depth (PD), mucosal recession (MR), defect resolution (a composite outcome defined as the simultaneous absence of PD > 5 mm, bleeding on probing [BOP] and/or suppuration [SUP], and bone level changes > 0.5 mm), plaque index (PI), BOP, suppuration on probing, suppuration on palpation, surgical duration, the Early Wound Healing Index (EHI), and patient-reported outcome measures (PROMs), including aesthetic self-evaluation.

PROMs will assess patients' perception of surgery, pain intensity, perceived swelling, perceived bleeding, and analgesic intake.

Clinical measurements will be recorded at baseline and at 6, 12, 18, and 24 months. EHI will be assessed at 1 and 2 weeks postoperatively. Radiographic bone levels at 12 and 24 months will be compared with those recorded on radiographs obtained at baseline. All PROMs variables, as well as aesthetic self-evaluation, will be collected using specially designed questionnaires completed by the patients. PROMs data will be recorded at 4, 8, and 12 hours after surgery on the day of surgery (day 0), and daily from postoperative day 2 to day 7. Aesthetic self-evaluation will be recorded at baseline and at 6, 12, and 24 months postoperatively.

Studietyp

Interventionell

Inskrivning (Faktisk)

32

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Roma, Italien, 00100
        • George Eastman Dental Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  • · Be able and willing to provide consent and sign the informed consent form.

    • Be able and willing to comply with study procedures and follow-up appointments required by the study protocol.
    • Age>18 years
    • Presence of at least one implant affected with peri-implantitis, defined as the following con-dition: at least one site presenting peri-implant probing depth (PPD) >6 mm and simultane-ous presence of profuse BoP/SUP and a radiographically documented change in bone level greater than initial bone remodeling. In the likely event that a baseline radiographic image is absent, the bone level will be compared to where it would likely have been at the time of implant insertion and a difference of >3 mm from that level will be considered.
    • Implants in function (i.e. loaded) for at least 1 year.
    • Screw- and cement-retained suprastructures for both fixed and removable prostheses.

Exclusion Criteria:

  • Compromised systemic health which contraindicates the study procedures.
  • Pregnant or nursing women.
  • Cigarette smoking>5 per day
  • Systemic conditions compromising healing (i.e. diabetes mellitus). Patients with diabe-tes mellitus types I or II will be asked to provide information regarding their most re-cent HbA1c values. Only patients with HbA1c<7% will be enrolled.
  • Patients taking medications known to interfere with gingival or bone metabolism.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Xenograft+collagen membrane
Reconstructive approach (Xenograft+collegen membrane)

For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.

Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.

Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap.

Experimentell: Xenograft+collagen membrane+autologous soft tissue graft
Reconstructive approach (Xenograft+collegen membrane) plus soft tissue graft (autologous, harvested as FGG)

For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.

Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.

Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Clinical attachment level
Tidsram: change from baseline to: 6, 12, 18, 24 months
linear distance (mm) from the implant platform to the bottom of the pocket
change from baseline to: 6, 12, 18, 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Probing depth
Tidsram: 6, 12, 18, 24 months
linear distance (mm) from the gingival margin to the bottom of the pocket
6, 12, 18, 24 months
Disease resolution
Tidsram: 6, 12, 18, 24 months
No PD greater than or equal to 5 mm and simultaneous absence of BOP/SUP and no more than 0.5 mm change between 2 weeks and 12 and 24 months on radiograph
6, 12, 18, 24 months
Mucosal recession
Tidsram: 6, 12, 18, 24 months
linear distance (mm) from the implant platform to the gingival margin
6, 12, 18, 24 months
plaque index (minimum value 0, maximum 1)
Tidsram: 6, 12, 18, 24 months
binary outcome: yes/ no detected running the probe into the peri-implant sulcus
6, 12, 18, 24 months
profuse bleeding
Tidsram: 6, 12, 18, 24 months
abundant bleeding evoked upon probing immediately after
6, 12, 18, 24 months
BOP
Tidsram: 6, 12, 18, 24 months
bleeding upon probing: bleeding evoked upon probing after 1 second
6, 12, 18, 24 months
suppuration
Tidsram: 6, 12, 18, 24 months
Binary: yes or no, detected upon probing or digital palpation
6, 12, 18, 24 months
Gingival thickness
Tidsram: 6, 12, 18, 24 months
Measured in a horizontal direction at 1 mm from the gingival margin
6, 12, 18, 24 months
Radiographic bone levels
Tidsram: 2 weeks, 12 months, 24 months
radiographic bone level changes between the 2 week and 12 and 24 month follow-ups
2 weeks, 12 months, 24 months
PROMs - Patient perception of surgery
Tidsram: 4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
Assessed using a 100-mm visual analog scale (VAS), where higher scores indicate a more positive perception of the surgical procedure.
4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
PROMs - Patient-reported pain intensity
Tidsram: 4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
Assessed using a 100-mm visual analog scale (VAS), where higher scores indicate greater pain intensity.
4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
PROMs - Patient-reported swelling
Tidsram: 4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
Assessed using a 100-mm visual analog scale (VAS), where higher scores indicate greater perceived swelling.
4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
PROMs - Patient-reported bleeding
Tidsram: 4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
Assessed using a 100-mm visual analog scale (VAS), where higher scores indicate greater perceived bleeding.
4 hours, 8 hours, 12 hours, and Days 2-7 after surgery
PROMs - Analgesic consumption
Tidsram: 12 hours after surgery and daily from day 2 through day 7 after surgery
Number of analgesic tablets consumed by the patient during the first postoperative week.
12 hours after surgery and daily from day 2 through day 7 after surgery
PROMs - aesthetic self-evaluation
Tidsram: Baseline, 6 months, 12 months, and 24 months
Assessed using a 100-mm visual analog scale (VAS), where higher scores indicate greater satisfaction with the esthetic outcome.
Baseline, 6 months, 12 months, and 24 months
Early wound healing
Tidsram: 1 week and 2 weeks after surgery
Wound healing scores ranging from 1 to 5 by the surgeon
1 week and 2 weeks after surgery
Surgical duration
Tidsram: at the surgery
The interval between the initial incision and placement of the final suture, measured in minutes.
at the surgery

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Luca Cordaro, MD, PhD, G. Eastman Dental Hospital Rome, Italy

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 februari 2021

Primärt slutförande (Faktisk)

1 januari 2025

Avslutad studie (Faktisk)

1 januari 2025

Studieregistreringsdatum

Först inskickad

23 mars 2020

Först inskickad som uppfyllde QC-kriterierna

25 mars 2020

Första postat (Faktisk)

26 mars 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

24 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

19 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 18117 (Annan identifierare: City of Hope Medical Center)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera